These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 31454075

  • 1. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestions From a Real-Life Italian Multicenter Experience.
    Vernieri F, Paolucci M, Altamura C, Pasqualetti P, Mastrangelo V, Pierangeli G, Cevoli S, D'Amico D, Grazzi L.
    Headache; 2019 Sep; 59(8):1300-1309. PubMed ID: 31454075
    [Abstract] [Full Text] [Related]

  • 2. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.
    Tassorelli C, Aguggia M, De Tommaso M, Geppetti P, Grazzi L, Pini LA, Sarchielli P, Tedeschi G, Martelletti P, Cortelli P.
    J Headache Pain; 2017 Dec; 18(1):66. PubMed ID: 28667550
    [Abstract] [Full Text] [Related]

  • 3. Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
    de Tommaso M, Brighina F, Delussi M.
    Eur Neurol; 2019 Dec; 81(1-2):37-46. PubMed ID: 31013496
    [Abstract] [Full Text] [Related]

  • 4. Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting.
    Santoro A, Fontana A, Miscio AM, Zarrelli MM, Copetti M, Leone MA.
    Neurol Sci; 2017 Oct; 38(10):1779-1789. PubMed ID: 28726049
    [Abstract] [Full Text] [Related]

  • 5. Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data.
    Ornello R, Guerzoni S, Baraldi C, Evangelista L, Frattale I, Marini C, Tiseo C, Pistoia F, Sacco S.
    J Headache Pain; 2020 Apr 25; 21(1):40. PubMed ID: 32334534
    [Abstract] [Full Text] [Related]

  • 6. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M, Gallardo VJ, Alpuente A, Pozo-Rosich P.
    J Headache Pain; 2020 Jul 11; 21(1):88. PubMed ID: 32652924
    [Abstract] [Full Text] [Related]

  • 7. Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
    Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD.
    J Headache Pain; 2016 Dec 11; 17(1):84. PubMed ID: 27640152
    [Abstract] [Full Text] [Related]

  • 8. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C.
    J Headache Pain; 2022 Sep 17; 23(1):123. PubMed ID: 36115947
    [Abstract] [Full Text] [Related]

  • 9. Wear-Off of OnabotulinumtoxinA Effect Over the Treatment Interval in Chronic Migraine: A Retrospective Chart Review With Analysis of Headache Diaries.
    Ruscheweyh R, Athwal B, Gryglas-Dworak A, Frattale I, Latysheva N, Ornello R, Pozo-Rosich P, Sacco S, Torres Ferrus M, Stark CD.
    Headache; 2020 Sep 17; 60(8):1673-1682. PubMed ID: 32797631
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin injection in the management of chronic migraine: the Saudi experience with a proposal for a new protocol.
    Algahtani H, Shirah B, Sukkar G, Bukhari H, Meftah I, Alhazmi A, Alshareef A, Algethami A, Alshanqiti A, Andeejani M.
    Acta Neurol Belg; 2021 Dec 17; 121(6):1783-1787. PubMed ID: 33058053
    [Abstract] [Full Text] [Related]

  • 11. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E, Martínez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J.
    Headache; 2014 Jun 17; 54(6):987-95. PubMed ID: 24673487
    [Abstract] [Full Text] [Related]

  • 12. Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
    Aicua-Rapun I, Martínez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, Porqueres E, Herrero S, Iglesias F, Guerrero AL.
    J Headache Pain; 2016 Dec 17; 17(1):112. PubMed ID: 27957623
    [Abstract] [Full Text] [Related]

  • 13. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group.
    J Headache Pain; 2021 May 03; 22(1):35. PubMed ID: 33941080
    [Abstract] [Full Text] [Related]

  • 14. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study.
    Lee MJ, Lee C, Choi H, Chung CS.
    J Neurol Sci; 2016 Apr 15; 363():51-4. PubMed ID: 27000220
    [Abstract] [Full Text] [Related]

  • 15. [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
    Bernhard MK, Bertsche A, Syrbe S, Weise S, Merkenschlager A.
    Fortschr Neurol Psychiatr; 2014 Jan 15; 82(1):39-42. PubMed ID: 24446117
    [Abstract] [Full Text] [Related]

  • 16. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.
    J Neurol Neurosurg Psychiatry; 2015 Sep 15; 86(9):996-1001. PubMed ID: 25500317
    [Abstract] [Full Text] [Related]

  • 17. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
    Suzuki K, Iizuka T, Sakai F.
    Intern Med; 2007 Sep 15; 46(13):959-63. PubMed ID: 17603233
    [Abstract] [Full Text] [Related]

  • 18. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct 15; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 19. Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life.
    Tassorelli C, Tedeschi G, Sarchielli P, Pini LA, Grazzi L, Geppetti P, De Tommaso M, Aguggia M, Cortelli P, Martelletti P.
    Expert Rev Neurother; 2018 Feb 15; 18(2):167-176. PubMed ID: 29280408
    [Abstract] [Full Text] [Related]

  • 20. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
    Domínguez C, Vieites-Prado A, Pérez-Mato M, Sobrino T, Rodríguez-Osorio X, López A, Campos F, Martínez F, Castillo J, Leira R.
    Headache; 2018 Jan 15; 58(1):78-87. PubMed ID: 29131327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.